Why targeted drug doesn't benefit patients with early-stage lung cancer

The drug erlotinib is highly effective in treating advanced-stage lung cancer patients whose tumors have a particular gene mutation, but when the same drug is used for patients with early-stage tumors with the same gene change, they fare worse than if they took nothing. This study might explain why.